US-based ALung Technologies has introduced new Hemolung CR4 Controller, a next generation extracorporeal carbon dioxide removal (ECCO2R) system.
The new system, which is part of the Hemolung Respiratory Assist System (RAS), offers minimally invasive extracorporeal CO2 removal as an alternative or supplement to mechanical ventilation for patients suffering from acute respiratory failure.
ALung Technologies chairman and CEO Peter DeComo said: "The development of the Hemolung CR4 Controller represents our commitment to making ECCO2R systems that are safe, simple and effective.
"In the coming months, we will pair this new controller with an updated Hemolung Cartridge Kit featuring a fully pre-connected circuit to further simplify the delivery of Hemolung therapy."
The system features a 360 degree handle and larger casters for easy guiding and facilitates patient ambulation from any position.
It also features a new quad-head vacuum pump that generates sweep gas flow with significantly less noise and an improved oxygen circuit for increased safety and reliability.
ALung will exhibit the system at the International Symposium of Intensive Care and Emergency Medicine (ISICEM) in Brussels, Belgium, which will take place from 17 to 20 March 2015.
The company noted that the device has been launched on a limited basis to reference centers, which will evaluate the product in clinical use, and full commercial release is being planned in the second half of this year.
Image: The Hemolung CR4 Controller provides extracorporeal carbon dioxide removal for patients suffering from acute respiratory failure. Photo: courtesy of ALung Technologies, Inc.